Evidence-based therapy of Raynaud's syndrome;Evidenzbasierte therapie des Raynaud-syndroms

Zeitschrift fur Rheumatologie

Volumn 65, Issue 4, 2006, Pages 285-289

  Distler, M ^a   Distler, J ^b   Ciurea, A ^c   Kyburz, D ^c   Muller Ladner U ^d   Reich, K ^a,e   Distler, O ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d KERCKHOFF HEART CENTER   (Germany)

^e Dermatologikum Hamburg ^*  (Germany)

Author keywords

Angiotensin II receptor type 1 antagonists; Calcium channel blockers; Phosphodiesterase V inhibitors; Prostacycline analogues; Raynaud's syndrome; Serotonin reuptake inhibitors; Systemic sclerosis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; FELODIPINE; FLUOXETINE; ILOPROST; LOSARTAN; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; VARDENAFIL; VASODILATOR AGENT;

CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; PERIPHERAL CIRCULATION; POLYMYOSITIS; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALCIUM CHANNEL BLOCKERS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EPOPROSTENOL; EVIDENCE-BASED MEDICINE; HUMANS; PHOSPHODIESTERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; RECEPTORS, ENDOTHELIN; SEROTONIN UPTAKE INHIBITORS; SULFONAMIDES; VASODILATOR AGENTS;

EID: 33746438870     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-006-0068-x     Document Type: Review

References (38)

1. Anderson ME, Moore TL, Hollis S et al. (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 41: 324-328
2. Arosio E, Montesi G, Zannoni M et al. (1989) Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon. Angiology 40: 633-638
3. Bali G, Aberer E (2003) Iloprost therapy in systemic sclerosis. Hautarzt 54: 845-851
4. Belch JJ, Capell HA, Cooke ED et al. (1995) Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 54: 197-200
5. Brennan P, Silman A, Black C et al. (1993) Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 32: 357-361
6. Caglayan E, Huntgeburth M, Karasch T et al. (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166: 231-233
7. Challenor VF, Waller DG, Hayward RA et al. (1991) Subjective and objective assessment of enalapril in primary Raynaud's phenomenon. Br J Clin Pharmacol 31: 477-480
8. Coffman JD, Rasmussen HM (1985) Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon. Circulation 72: 466-470
9. Coleiro B, Marshall SE, Denton CP et al. (2001) Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40: 1038-1043
10. Della Bella S, Molteni M, Mocellin C et al. (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 65: 73-83
11. De Trafford JC, Lafferty K, Potter CE et al. (1988) An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 2: 167-170
12. Diehm C, Muller-Buhl U, Mechterscheimer U, Morl H (1984) Local treatment with isosorbide dinitrate ointment in Raynaud's phenomenon. Vasa 13: 72-74
13. Dziadzio M, Denton CP, Smith R et al. (1999) Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42: 2646-2655
14. Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112: 2980-2985
15. Goodfield MJ, Hume A, Rowell NR (1990) The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. Br J Rheumatol 29: 89-91
16. Grader-Beck T, Wigley FM (2005) Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 31: 465-481
17. Kallenberg CG, Wouda AA, Meems L, Wesseling H (1991) Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 40: 313-315
18. Ko GD, Berbrayer D (2002) Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev 7: 328-335
19. Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 3985-3993
20. La Civita L, Pitaro N, Rossi M et al. (1993) Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumatol 32: 524-525
21. Muir AH, Robb R, McLaren M et al. (2002) The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc Med 7:265-267
22. Pope J, Fenlon D, Thompson A et al. (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev CD000953
23. Pope J, Fenlon D, Thompson A et al. (2000) Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev CD000956
24. Rademaker M, Cooke ED, Almond NE et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298: 561-564
25. Ramos-Casals M, Brito-Zeron P, Nardi N et al. (2004) Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) 43: 1454-1456
26. Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprost administration over 21 days as an effective therapy in systemic scleroderma - case report and review of the literature. Z Rheumatol 57: 118-124
27. Ruch DS, Holden M, Smith BP et al. (2002) Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up. J Hand Surg [Am] 27: 258-264
28. Rustin MH, Almond NE, Beacham JA et al. (1987) The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol 117: 751-758
29. Sapadin AN, Fleischmajer R (2002) Treatment of scleroderma. Arch Dermatol 138: 99-105
30. Schmidt JF, Valentin N, Nielsen SL (1989) The clinical effect of felodipine and nifedipine in Raynaud's phenomenon. Eur J Clin Pharmacol 37: 191-192
31. Thompson AE, Pope JE (2005) Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 44: 145-50
32. Thompson AE, Shea B, Welch V et al. (2001) Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44: 1841-1847
33. Torley HI, Madhok R, Capell HA et al. (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50: 800-804
34. Van der Meer J, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon. Vasa Suppl 18: 71-75
35. Vayssairat M (1996) Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 23: 1917-1920
36. Wigley FM (2002) Clinical practice. Raynaud's Phenomenon. N Engl J Med 347: 1001-1008
37. Wigley FM, Wise RA, Seibold JR et al. (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120: 199-206
38. Wigley FM, Korn JH, Csuka ME et al. (1998) Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41: 670-677